Galderma Sustainability Profile
Galderma, a leading global dermatology company, is headquartered in the United States and operates extensively across Europe, Asia, and Latin America. Founded in 1981, Galderma has established itself as a pioneer in the field of medical and aesthetic dermatology, focusing on innovative solutions for skin health. The company is renowned for its core products, including the Restylane® range of dermal fillers and the Sculptra® aesthetic treatment, which are distinguished by their unique formulations and proven efficacy. Galderma's commitment to research and development has positioned it as a trusted name in the industry, with a strong market presence and notable achievements in advancing dermatological care. With a focus on enhancing skin health and beauty, Galderma continues to lead the way in dermatological innovation.
DitchCarbon Score
How does Galderma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Galderma's score of 37 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Galderma, headquartered in the US, currently does not have available emissions data for the most recent year. As a current subsidiary of Galderma Laboratories, L.P., emissions data may be inherited from its parent company, Galderma Group AG, but specific figures are not disclosed. Despite the absence of specific emissions data, Galderma is committed to addressing climate change through various initiatives. However, there are no documented reduction targets or climate pledges available at this time. The company is part of a broader industry context that increasingly prioritises sustainability and carbon footprint reduction, aligning with global efforts to mitigate climate impacts. As Galderma continues to develop its climate strategy, stakeholders can anticipate future commitments and potential emissions disclosures that reflect its dedication to environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 9,800,000 | 0,000,000 |
| Scope 2 | 4,200,000 | 000,000 |
| Scope 3 | - | 000,000,000 |
How Carbon Intensive is Galderma's Industry?
How Carbon Intensive is Galderma's Location?
Galderma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Galderma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Valeant Pharmaceuticals North America LLC
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.